User: Guest  Login
Document type:
journal article 
Author(s):
Tedesco-Silva, H; Vitko, S; Pascual, J; Eris, J; Magee, JC; Whelchel, J; Civati, G; Campbell, S; Alves-Filho, G; Bourbigot, B; Garcia, VD; Leone, J; Esmeraldo, R; Rigotti, P; Cambi, V; Haas, T; 2306 and 2307 study groups 
Title:
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. 
Abstract:
The proliferation signal inhibitor everolimus (Certican), has demonstrated efficacy with full-dose cyclosporine (CsA) (Neoral). Two multicenter randomized controlled studies were performed to compare 12-month efficacy and safety of everolimus 1.5 and 3.0 mg/day with reduced-dose CsA. Study 1 enrolled 237 de novo renal allograft recipients, randomizing 222 nonblack patients to either everolimus 1.5 or 3.0 mg/day, with the Neoral) dose guided by C(2) (monitoring of CsA concentration 2 h after dosi...    »
 
Journal title abbreviation:
Transpl Int 
Year:
2007 
Journal volume:
20 
Journal issue:
Pages contribution:
27-36 
Language:
eng 
Print-ISSN:
0934-0874 
TUM Institution:
Abteilung für Nephrologie